Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities
Briefings in Bioinformatics · 22.11.2023 · 25 (1)
DOI: 10.1093/bib/bbad470 ↗Kurz gefasst
Fachartikel in der Zeitschrift Briefings in Bioinformatics, online erschienen am 27.12.2023. Verfasst von Song Zhai und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA. Hauptthemen laut MEDLINE: Genetic Risk Score, Genome-Wide Association Study. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Polygenic risk scores (PRSs) have emerged as promising tools for the prediction of human diseases and complex traits in disease genome-wide association studies (GWAS). Applying PRSs to pharmacogenomics (PGx) studies has begun to show great potential for improving patient stratification and drug response prediction. However, there are unique challenges that arise when applying PRSs to PGx GWAS beyond those typically encountered in disease GWAS (e.g. Eurocentric or trans-ethnic bias). These challenges include: (i) the lack of knowledge about whether PGx or disease GWAS/variants should be used in the base cohort (BC); (ii) the small sample sizes in PGx GWAS with corresponding low power and (iii) the more complex PRS statistical modeling required for handling both prognostic and predictive effects simultaneously. To gain insights in this landscape about the general trends, challenges and possible solutions, we first conduct a systematic review of both PRS applications and PRS method development in PGx GWAS. To further address the challenges, we propose (i) a novel PRS application strategy by leveraging both PGx and disease GWAS summary statistics in the BC for PRS construction and (ii) a new Bayesian method (PRS-PGx-Bayesx) to reduce Eurocentric or cross-population PRS prediction bias. Extensive simulations are conducted to demonstrate their advantages over existing PRS methods applied in PGx GWAS. Our systematic review and methodology research work not only highlights current gaps and key considerations while applying PRS methods to PGx GWAS, but also provides possible solutions for better PGx PRS applications and future research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biostatistics and Research Decision Sciences, Merck & Co., Inc., Rahway, NJ 07065, USA.
- Biostatistics and Research Decision Sciences, Merck & Co., Inc., North Wales, PA 19454, USA.
ORCID-Profile: Judong Shen
Zitieren
APA
Zhai, S., Mehrotra, D. V., & Shen, J. (2023). Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities. Briefings in Bioinformatics, 25(1). https://doi.org/10.1093/bib/bbad470
Vancouver
Zhai S, Mehrotra DV, Shen J. Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities. Briefings in Bioinformatics. 2023;25(1). doi:10.1093/bib/bbad470
BibTeX
@article{Zhai2023,
author = {Zhai, Song and Mehrotra, Devan V and Shen, Judong},
title = {Applying polygenic risk score methods to pharmacogenomics GWAS: challenges and opportunities},
journal = {Briefings in Bioinformatics},
year = {2023},
volume = {25},
number = {1},
doi = {10.1093/bib/bbad470}
}
EUVIMED